References
- ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after comple-tion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60–62
- Dowsett M, Ebbs SR, Dixon JM, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combi-nation: influence of hormonal status and HER-2 in breast cancer_a study from the IMPACT trialists. J Clin Oncol 2005;23:2477–2492
- Dowsett M, Smith IE, Ebbs SR, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005;11:951-958s
- Dowsett M, Smith I, on behalf of the IMPACT Trialists. Greater Ki67 response after 2 weeks neoadjuvant treatment with anastrozole than with tamoxifen or anastrozole plus tamoxifen in the IMPACT trial: a potential predictor of relapse-free survival [abstract 2]. Breast Cancer Res Treat 2003;82: 56
Further reading
- Tao Y, Klause A, Vickers A, Bae K, Ellis M. Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials. Journal of Steroid Biochemistry & Molecular Biology 2005;95:91–95
- Winer EP, Hudis C, Burstein HJ, et al. Assessment on the use of aromatase inhibitors as adjuvant therapy for post-menopausal women with hormone receptor—positive breast cancer: Status Report 2004. J Clin Oncol 2004; 23:619–629